{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:03:17Z","timestamp":1756339397853,"version":"3.44.0"},"reference-count":5,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Overview of:<\/jats:bold> van Dyck CH, Swanson CJ, Aisen P, <jats:italic>et al<\/jats:italic>. Lecanemab in Early Alzheimer's Disease. <jats:italic>N Engl J Med<\/jats:italic>. 2023;388:9\u201321<\/jats:p>","DOI":"10.1136\/dtb.2023.000005","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T13:20:11Z","timestamp":1675257611000},"page":"37-37","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Evidence for lecanemab in early Alzheimer\u2019s disease"],"prefix":"10.1136","volume":"61","member":"239","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"2025082701482097000_61.3.37.1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2025082701482097000_61.3.37.2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMe2214981","article-title":"Moving the needle on alzheimer\u2019s disease with an anti-oligomer antibody","volume":"388","author":"Gandy","year":"2023","journal-title":"N Engl J Med"},{"key":"2025082701482097000_61.3.37.3","unstructured":"Wolfe S . Letter to the FDA urging postponement of the approval decision regarding lecanemab for treatment of alzheimer\u2019s disease. 2023. Available: https:\/\/www.citizen.org\/article\/letter-to-the-fda-urging-postponement-of-the-approval-decision-regarding-lecanemab-for-treatment-of-alzheimers-disease\/ [Accessed 18 Jan 2023]."},{"key":"2025082701482097000_61.3.37.4","doi-asserted-by":"crossref","unstructured":"Reish NJ , Jamshidi P , Stamm B , et al . Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med 4, 2023. doi:10.1056\/NEJMc2215148","DOI":"10.1056\/NEJMc2215148"},{"key":"2025082701482097000_61.3.37.5","unstructured":"US Food and Drug Administration . FDA grants accelerated approval for alzheimer\u2019s disease treatment. 2023. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment [Accessed 20 Jan 2023]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2023.000005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:48:29Z","timestamp":1756284509000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2023.000005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2,22]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/dtb.2023.000005"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2023.000005","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}